Sign Up to like & get
recommendations!
0
Published in 2020 at "Movement Disorders"
DOI: 10.1002/mds.28359
Abstract: Funding sources and conflict of interest – This trial was funded initially by Ionis and subsequently by Roche. The authors received no additional funding for this work and the authors declare that there are no…
read more here.
Keywords:
oligonucleotide therapy;
complicating intrathecal;
antisense oligonucleotide;
hydrocephalus complicating ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Nature Reviews Rheumatology"
DOI: 10.1038/s41584-018-0128-z
Abstract: from patients with OA compared with undamaged control cartilage. Furthermore, in the destabilization of the medial meniscus mouse model of OA, intra-articular adenoviral delivery of Itgbl1 reduced cartilage damage and osteophyte formation. “As a long-term…
read more here.
Keywords:
oligonucleotide therapy;
antisense oligonucleotide;
new antisense;
Sign Up to like & get
recommendations!
1
Published in 2022 at "In Vivo"
DOI: 10.21873/invivo.12779
Abstract: Background/Aim: An early evaluation concerning the effectiveness of supportive oligonucleotide therapy (SOT) in cancer as a monotherapy and in combination with other types of treatment. Patients and Methods: This study evaluated the clinical condition and…
read more here.
Keywords:
sot;
therapy sot;
supportive oligonucleotide;
therapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Infectious Disease Reports"
DOI: 10.3390/idr14060084
Abstract: Antisense therapy is widely used as an alternative therapeutic option for various diseases. RNA interference might be effective in infections, through the degradation of messenger RNA and, therefore, translation process. Hence, proteins essential for microorganisms…
read more here.
Keywords:
supportive oligonucleotide;
lyme disease;
therapy;
potential treatment ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14112389
Abstract: Antisense oligonucleotides (ASOs) are disease-modifying agents affecting protein-coding and noncoding ribonucleic acids. Depending on the chemical modification and the location of hybridization, ASOs are able to reduce the level of toxic proteins, increase the level…
read more here.
Keywords:
antisense oligonucleotide;
neurology;
neurological disorders;
therapy nervous ... See more keywords